BiotechTube
Home/Castle Creek Biosciences/Matthew Gantz, M.B.A.
MG

Matthew Gantz, M.B.A.

Chairman and Chief Executive Officer

Castle Creek Biosciences

Therapeutic Areas

Rare Genetic DiseasesDermatologyConnective Tissue Disorders

Castle Creek Biosciences Pipeline

DrugIndicationPhase
D-Fi (dabocemagene autoficel / FCX-007)Dystrophic Epidermolysis Bullosa (DEB)Phase 3

Leadership Team at Castle Creek Biosciences

DC
David Chu, M.D., Ph.D., F.A.A.D.
Chief Medical Officer
MT
Michael Townsley, R.N.
Head of Quality Assurance
CJ
Christopher J. Larson, M.S., MLS (ASCP)
Vice President, Quality Control
RW
Rhea Williams, M.P.H.
Vice President, Regulatory Affairs
MC
Matthew Crabtree
Vice President, Finance
RB
Robin Blumenthal, Ph.D.
Associate Vice President, Clinical Operations
View full Castle Creek Biosciences profile